Uterine serous cancer constitutes up to 10% of all endometrial tumors, and represents the most biologically aggressive variant of type II EC. This article will describe the most salient molecular ...
News Medical on MSN3mon
The threat of serous uterine cancer: A new perspectiveMost uterine cancers have excellent five-year survival rates – up to 95% for localized cancer. Serous uterine cancer is an ...
For patients with advanced or recurrent endometrial cancer, first-line Lenvima plus Keytruda didn’t significantly improve ...
Q-901 is under clinical development by Qurient and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II drugs for Endometrial Cancer have a 22% phase transition success rate ...
Defactinib hydrochloride is under clinical development by Verastem and currently in Phase II for Non-Small Cell Lung Cancer.
Expert Rev Anticancer Ther. 2012;12(1):41-49. © 2012 Expert Reviews Ltd. Uterine serous cancer (USC) is a highly aggressive variant of endometrial cancer. USC is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback